摘要
目的探讨布地奈德联合阿奇霉素序贯疗法对支原体肺炎(Mycoplasma Pneumonia,MPP)患儿血清炎性因子的影响。方法便利选取2022年1-12月贵州省黔西南州妇幼保健院收治的120例MPP患儿为研究对象,按随机数表法分为两组。在常规治疗基础上,对照组(60例)采用阿奇霉素序贯疗法,观察组(60例)采用布地奈德联合阿奇霉素序贯疗法。对比两组治疗总有效率、临床症状消失时间、呼吸困难指数、血清炎性因子水平以及不良反应发生情况。结果观察组的总有效率为93.33%,高于对照组的71.67%,差异有统计学意义(χ^(2)=9.755,P=0.002);观察组退热、止咳、啰音消失时间均短于对照组,差异有统计学意义(t=13.669、15.581、2.769,P均<0.05);治疗后观察组呼吸困难指数低于对照组,差异有统计学意义(Z=3.449,P<0.05);治疗后,观察组C反应蛋白、降钙素原水平均低于对照组,差异有统计学意义(t=2.465、15.423,P均<0.05);两组不良反应比较,差异无统计学意义(χ^(2)=0.000,P=1.000)。结论布地奈德联合阿奇霉素序贯疗法能够有效改善MMP患儿的炎性因子水平、呼吸困难指数,加快临床症状消失,安全性较高。
Objective To investigate the effect of budesonide combined with azithromycin sequential therapy on serum inflammatory factors in children with mycoplasma pneumonia(MPP).Methods 120 cases of children with MPP admit-ted to Qianxinan Prefecture Maternal and Child Health Hospital from January 2022 to December 2022 were selected conveniently as the study objects and divided into two groups according to the randomized numerical table method.On the basis of conventional treatment,azithromycin sequential therapy was used in the control group(60 cases),and budesonide combined with azithromycin sequential therapy was used in the observation group(60 cases).The two groups were compared in terms of total effective rate of treatment,time to disappearance of clinical symptoms,dyspnea index,serum inflammatory factor level and the occurence of adverse reactions.Results The total effective rate of the observation group was 93.33%,significantly higher than that of the control group,which was 71.67%,and the differ-ence was statistically significant(χ^(2)=9.755,P=0.002).The time for fever reduction,cough suppression and disappear-ance of rales in the observation group was shorter than that in the control group,and the differences were statistically significant(t=13.669,15.581,2.769,all P<0.05).The dyspnea index of the observation group was significantly lower than that of the control group after treatment,the difference was statistically significant(Z=3.449,P<0.05),and the av-erage of C-reactive protein and procalcitonin was lower than that of the control group,the differences were statistically significant(t=2.465,15.423,all P<0.05),and there was no statistically significant difference in the comparison of ad-verse reactions between two groups(χ^(2)=0,P=1.000).Conclusion Budesonide combined with azithromycin sequential therapy can effectively improve the level of inflammatory factors,dyspnea index,accelerate the disappearance of clini-cal symptoms in children with MMP,with high safety.
作者
周艳
李万琼
文达梅
ZHOU Yan;LI Wanqiong;WEN Damei(Department of Pediatrics,Qianxinan Prefecture Maternal and Child Health Hospital,Xingyi,Guizhou Province,562400 China)
出处
《中外医疗》
2024年第7期88-91,104,共5页
China & Foreign Medical Treatment
关键词
支原体肺炎
布地奈德
阿奇霉素
序贯疗法
炎性因子
Mycoplasma pneumonia
Budesonide
Azithromycin
Sequential therapy
Inflammatory factor
